Trimerbody

LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies with higher multivalence and multispecificity than the immunoglobulins, which are currently most prevalent on the market. 
 
Our drug candidates are derived from in-house R&D and our collaborations with reference research centers and other companies. We have several proprietary programs developing in multiple therapeutic areas, including immune-oncology, which is a high-growth area for companies and investors. LeadArtis offers an opportunity to participate in the development of cutting-edge immunomodulatory therapies against cancer.
 
By creating new medicines, we can create hope for future patients suffering from cancers for which current therapies are inadequate. 
 
Trimerbody® is a registered trademark and is covered by international patents.

Latest News

Clave Capital invests in Leadartis in a funding round of more than €1,600,000
14-05-2021

Clave Capital, through the fund Navarra Tech Transfer, consolidates with this new operation its...

Sodena and Capital Cell invest €1.600.000 in the biopharmaceutical Leadartis
30-04-2021

The entry of funds into leadartis' shareholding is part of a round of financing closed by...

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research
02-04-2021